Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study

BACKGROUND: For second-line antiretroviral therapy, WHO recommends a boosted protease inhibitor plus nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs). However, concerns about toxicity and cross-resistance motivated a search for regimens that do not contain NRTIs. We aimed to assess...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Lancet HIV
Autores principales: La Rosa, Alberto M, Harrison, Linda J, Taiwo, Babafemi, Wallis, Carole L, Zheng, Lu, Kim, Peter, Kumarasamy, Nagalingeswaran, Hosseinipour, Mina C, Jarocki, Bernadette, Mellors, John W, Collier, Ann C
Formato: Artigo
Lenguaje:Inglês
Publicado: 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4914044/
https://ncbi.nlm.nih.gov/pubmed/27240787
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3018(16)30011-X
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares